LSD1: an emerging face in altering the tumor microenvironment and enhancing immune checkpoint therapy

Journal of Biomedical Science

Review

Dan-Dan Shen¹  Jin-Yuan Zhao²  Ting Guo²  Hong-Min Liu²  M A A Mamun²  Yu Zhang²  Yi-Chao Zheng²  Li-Juan Zhao³ 

[1] Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China;Key Laboratory of Endometrial Disease Prevention and Treatment Zhengzhou China, The Third Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China;Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, China, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Henan Province for Drug Quality and Evaluation, Institute of Drug Discovery and Development, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, 450001, Zhengzhou, China;Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, China, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Henan Province for Drug Quality and Evaluation, Institute of Drug Discovery and Development, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, 450001, Zhengzhou, China;State Key Laboratory of Esophageal Cancer Prevention and Treatment, Academy of Medical Sciences, Zhengzhou University, 450052, Zhengzhou, China;

关键词: LSD1;    Tumor microenvironment;    Immunosuppression;    Immune checkpoint blockade;    Epigenetic TME regulation;   

DOI  :  10.1186/s12929-023-00952-0

 received in 2023-04-19, accepted in 2023-07-17,  发布年份 2023

来源: Springer

【 摘 要 】

Dysregulation of various cells in the tumor microenvironment (TME) causes immunosuppressive functions and aggressive tumor growth. In combination with immune checkpoint blockade (ICB), epigenetic modification-targeted drugs are emerging as attractive cancer treatments. Lysine-specific demethylase 1 (LSD1) is a protein that modifies histone and non-histone proteins and is known to influence a wide variety of physiological processes. The dysfunction of LSD1 contributes to poor prognosis, poor patient survival, drug resistance, immunosuppression, etc., making it a potential epigenetic target for cancer therapy. This review examines how LSD1 modulates different cell behavior in TME and emphasizes the potential use of LSD1 inhibitors in combination with ICB therapy for future cancer research studies.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 3

Fig. 1

Fig. 1

Scheme 1

12888_2023_4959_Article_IEq1.gif